The presenter highlights a significant decline in Amgen's stock due to concerns over its drug's performance following negative news from Novartis.
The presenter attributes market weakness to Amgen's poor performance, suggesting a negative outlook for the stock.
Amgen is highlighted as one of the top holdings in SCHD, indicating a positive outlook based on its performance and role in the ETF.
2 of 7 days measured · shaded = no mentions
The blue horizontal line marks the plate's own 30-day score, shown above — it is not an average of the points around it. Each point is that single day's own score, computed the same way but over one day instead of the whole window.
First in this window: Everything Money · Sep 1, 2026
| BInvestor's Business Daily183k subs | 1 | 10.49 | BEAR | <1M |
| DStocks Galore - Stock Picks & Investing Insights28k subs | 1 | 8.39 | BEAR | <1M |
| BEverything Money411k subs | 1 | 6.77 | BULL | 6M+ |
| AI Stocks Lead, Blue Chips Lag In Down Session: AMD, Magnite, TVTX In Focus | Stock Market TodayWatch on YouTube ↗ | Investor's Business Daily | Sep 8, 2026 | 10.49 |
| Why September Could Be a Dangerous Month for InvestorsWatch on YouTube ↗ | Stocks Galore - Stock Picks & Investing Insights | Sep 10, 2026 | 8.39 |
| The ETF to BUY That Beats QQQ (And Why It Wins in 2026)Watch on YouTube ↗ | Everything Money | Sep 1, 2026 | 6.77 |